Is Pfizer (PFE) Still a Safe Investment in 2024? A Deep Dive into the Pharmaceutical Giant

Pfizer has been a blue-chip stock for years, but with declining COVID-19 vaccine revenues and shifting market conditions, is it still a strong long-term investment?

In my latest analysis, I break down:

* Pfizer’s financial health and revenue trends
* The impact of falling vaccine sales on its bottom line
* Growth opportunities through new drug development and acquisitions
* Dividend stability and investor returns
* Risks facing the pharmaceutical industry

With increased competition and changing healthcare demands, investors need to assess whether Pfizer remains a solid buy.